title: Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice.
abstract: Despite significant advances in the management of acute coronary syndrome (ACS) and long-term antiplatelet therapy after an ACS event, patients continue to be at risk of further cardiovascular events. There is evidence that recurrent events are at least partly attributed to the persistent activation of the coagulation system after ACS. Various anticoagulants, including vitamin K antagonists (VKAs) and non-VKA oral anticoagulants, have been evaluated in patients post-ACS, in combination with antiplatelet therapy. The desired outcome would be a further reduction of recurrent cardiovascular events with low or acceptable levels of bleeding complications. Here, we provide an overview of the current clinical trial data of non-VKA oral anticoagulants, focusing on rivaroxaban in particular, for secondary prevention in patients with a recent ACS event.
authors.affiliation: Department of Cardiology, King's Mill Hospital, Sutton-in-Ashfield, Nottinghamshire, UK.
authors.forename: Ganesh Nallur
authors.initials: GN
authors.lastname: Shivu
authors.affiliation: Department of Cardiology, University Hospital of Wales, Cardiff, UK.
authors.forename: Nick
authors.initials: N
authors.lastname: Ossei-Gerning
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000517:prevention & control; D002986:Clinical Trials as Topic; D065427:Factor Xa Inhibitors / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D000069552:Rivaroxaban; D055502:Secondary Prevention; D013876:Thiophenes / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D065427:Factor Xa Inhibitors; D009025:Morpholines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D000069552:Rivaroxaban
keywords: acute coronary syndrome; anticoagulants; antiplatelet therapy